Thailand Amends Its Hazardous Substance Import Exemption Scheme and Adds R&D Testing Criteria

On January 5, 2026, Thailand's Ministry of Public Health published two separate notifications affecting how a hazardous substance import can qualify for exemption from the full notification, permit, and registration process that otherwise governs the activity. One is Amendment No. 2 to the Ministry's existing hazardous substance import exemption scheme, a finalized change to a framework that has been in force for some time already. The other sets out exemption criteria specifically for hazardous substances imported for education, testing, analysis, or research and development purposes. Both notifications refine the same underlying question, when a hazardous substance import qualifies for a lighter-touch exemption pathway rather than the full compliance track, but they do it through two distinct instruments issued on the same day.

A finalized amendment, not the still-draft new exemption rule

Companies tracking Thailand's hazardous substance exemption framework closely need to keep this January 5, 2026 amendment separate from a different, unrelated development: a proposed new set of import exemption rules that Thailand's FDA has put out for public consultation and that, as of mid-2026, remains in draft form and has not been finalized. DeeMED covered that draft proposal in a separate article, and it is easy to conflate the two because both concern hazardous substance import exemptions and both surfaced in the same general period. They are not the same instrument. Amendment No. 2 is a finalized, published change to the Ministry's existing exemption scheme, the one already governing which import scenarios can bypass full notification, permit, or registration requirements. The separate draft rule under public consultation would, if and when it is finalized, sit alongside or eventually replace parts of that existing scheme, but it has not reached that stage yet. Any company relying on either instrument for a compliance decision needs to confirm which one it is actually looking at before treating a requirement as settled.

What Amendment No. 2 actually is

Amendment No. 2 modifies the criteria and conditions under which Thailand's existing import exemption scheme applies. The underlying scheme itself already carves out certain import scenarios, previously registered products moving under specific conditions, quantities below a defined threshold, or substances destined for uses the Ministry has decided do not warrant full registration, from the notification, permit, and registration requirements that otherwise apply to hazardous substance imports. Amendment No. 2 refreshes those criteria rather than replacing the scheme wholesale. A company that has structured a recurring import around the existing exemption basis needs to check, substance by substance, whether Amendment No. 2 changed the specific condition its import currently relies on, since an exemption basis that held before January 5, 2026 is not automatically guaranteed to hold in its exact previous form after that date.

New exemption criteria for education, testing, and R&D imports

Published the same day, the second MOPH notification sets exemption criteria specifically for hazardous substances imported for education, testing, analysis, or research and development purposes. This is a distinct carve-out from the general exemption scheme that Amendment No. 2 modifies, aimed at a specific category of importer: universities, testing laboratories, contract research organizations, and manufacturers bringing in small quantities of a hazardous substance to run internal analysis or R&D work rather than to sell the substance commercially. Where an import genuinely serves one of these non-commercial purposes and meets the notification's criteria, it may now qualify for the lighter-touch exemption pathway instead of the full registration track that would otherwise apply to any hazardous substance entering Thailand.

Why the distinction between commercial and R&D import matters

Thailand's hazardous substance framework has historically applied the same registration and licensing burden regardless of whether the imported quantity was destined for commercial sale or for a single round of laboratory testing. A research institute importing a gram-scale quantity of a controlled substance to validate an analytical method faces a fundamentally different risk profile than a manufacturer importing drums of the same substance for commercial distribution, but the older framework did not always draw that line clearly in the exemption criteria themselves. The new R&D-specific notification gives the Ministry an explicit basis to treat these two import purposes differently, provided the importer can actually demonstrate that the import is for education, testing, analysis, or R&D and not a commercial use dressed up as one.

Who should be checking their current exemption basis now

Two groups of companies have a practical reason to look at these January 5, 2026 notifications now rather than later. The first is any company already relying on Thailand's general hazardous substance import exemption scheme for a recurring import, since Amendment No. 2 is a change to the same scheme that basis depends on, and confirming what specifically changed is a shorter exercise than discovering the gap the next time a shipment is declared. The second is any company importing hazardous substances for testing, analysis, or R&D purposes that has, up to now, been running that import through the full commercial registration track by default because no dedicated exemption criteria for that use case existed. That second group in particular may find that an import previously treated as requiring full registration now has a legitimate exemption pathway available, provided the actual use case and supporting documentation match what the notification requires.

A recurring pattern in how exemption schemes evolve

An import exemption scheme rarely stays static once it exists. Regulators tend to refine the boundaries of an exemption over time as they see how it is actually used in practice, tightening a condition that turns out to be exploited, loosening one that turns out to be unnecessarily restrictive for a legitimate use case, or adding an entirely new carve-out for a use case the original scheme did not contemplate. Amendment No. 2 and the R&D-specific notification both fit that pattern: one narrows or clarifies an existing pathway, the other adds a pathway that did not exist before. A company that treats an exemption basis as something confirmed once and never revisited is exposed to exactly this kind of drift, since the underlying scheme it relied on eighteen months ago is not guaranteed to be the same scheme in force today, even where the general shape of the exemption looks unchanged on the surface.

Building the R&D exemption into an import decision, not after the fact

A research institute or contract laboratory planning a hazardous substance import for testing or analysis purposes gets the most value out of the new R&D exemption criteria by checking eligibility before the import is scheduled, not after a shipment has already been declared under the default commercial track. That means confirming, ahead of time, that the substance, the quantity, and the stated purpose of the import genuinely match what the notification requires for the exemption to apply, and that the institution can document the non-commercial use if asked. An import that is structured from the outset around the R&D exemption's actual criteria has a much cleaner path through customs than one that tries to reclassify itself as R&D-purpose after already being declared under the standard commercial import process, since the documentation trail in the second scenario rarely lines up as cleanly with what the exemption notification expects to see.

What DeeMED is not confirming yet

Both notifications were published on January 5, 2026 by Thailand's FDA hazardous substance authority. DeeMED has not yet reviewed the full text of either notification in enough depth to state the specific quantity thresholds, documentation requirements, or substance categories the R&D exemption criteria cover, and this article deliberately does not invent those details. What is confirmed is that Amendment No. 2 is a finalized change to the existing general exemption scheme, that a separate R&D-specific exemption notification was published the same day, and that both are distinct from the still-draft new exemption rule that remains under public consultation as a separate matter entirely. Companies with a live import decision resting on either instrument should treat the underlying notification text, not a general summary, as the operative reference.

DeeMED tracks Thailand's hazardous substance exemption framework as part of our broader work on FDA jurisdiction and product scope for hazardous substances, since knowing whether a specific import qualifies for exemption in the first place is the question that determines everything else about how that import needs to be handled.